What is Zacks Research’s Estimate for VRTX Q1 Earnings?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Analysts at Zacks Research lowered their Q1 2025 EPS estimates for Vertex Pharmaceuticals in a note issued to investors on Thursday, January 23rd. Zacks Research analyst R. Department now anticipates that the pharmaceutical company will post earnings per share of $3.51 for the quarter, down from their prior estimate of $3.82. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is ($1.90) per share. Zacks Research also issued estimates for Vertex Pharmaceuticals’ Q2 2025 earnings at $3.76 EPS.

VRTX has been the subject of several other research reports. Citigroup initiated coverage on Vertex Pharmaceuticals in a research note on Thursday, November 14th. They issued a “buy” rating and a $575.00 price target for the company. Jefferies Financial Group raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $500.00 to $550.00 in a research note on Monday, December 9th. Wells Fargo & Company cut their target price on Vertex Pharmaceuticals from $555.00 to $460.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. HC Wainwright dropped their target price on shares of Vertex Pharmaceuticals from $600.00 to $535.00 and set a “buy” rating for the company in a research report on Friday, December 20th. Finally, BMO Capital Markets cut their price objective on Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating for the company in a research report on Friday, December 20th. Two analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $494.76.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX opened at $443.88 on Monday. Vertex Pharmaceuticals has a 1-year low of $377.85 and a 1-year high of $519.88. The firm has a market capitalization of $114.31 billion, a PE ratio of -223.06, a P/E/G ratio of 2.20 and a beta of 0.40. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. The business’s fifty day moving average price is $435.36 and its two-hundred day moving average price is $464.32.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. The company had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm’s revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the company earned $3.67 earnings per share.

Institutional Trading of Vertex Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Czech National Bank lifted its holdings in Vertex Pharmaceuticals by 6.2% during the 4th quarter. Czech National Bank now owns 55,838 shares of the pharmaceutical company’s stock worth $22,486,000 after purchasing an additional 3,260 shares during the last quarter. Whalen Wealth Management Inc. acquired a new position in Vertex Pharmaceuticals in the 3rd quarter valued at $662,000. Creative Planning grew its holdings in shares of Vertex Pharmaceuticals by 5.3% during the 2nd quarter. Creative Planning now owns 79,117 shares of the pharmaceutical company’s stock worth $37,084,000 after purchasing an additional 3,998 shares in the last quarter. Mizuho Securities USA LLC grew its stake in Vertex Pharmaceuticals by 289.0% during the third quarter. Mizuho Securities USA LLC now owns 77,393 shares of the pharmaceutical company’s stock worth $35,994,000 after buying an additional 57,497 shares in the last quarter. Finally, Nordea Investment Management AB raised its position in shares of Vertex Pharmaceuticals by 19.4% in the 4th quarter. Nordea Investment Management AB now owns 342,429 shares of the pharmaceutical company’s stock valued at $137,783,000 after buying an additional 55,739 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.